Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

作者： Ferdinando C. M. Cananzi , Bruno Lorenzi , Ajay Belgaumkar , Charlotte Benson , Ian Judson

关键词:

摘要: Purpose Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of gastrointestinal tract. The introduction tyrosine kinase inhibitors (TKIs) has lead to increasing use combination medical and surgical therapy. aim this study was look at outcomes from a series surgically treated GISTs determine prognostic factors in context multimodal

参考文章(60)

Helen E. Remotti, Frank Aldenborg, Jeanne M. Meis-Kindblom, Lars Gunnar Kindblom, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology. ,vol. 152, pp. 1259- 1269 ,(1998)

Hayrullah Derici, Haluk R. Unalp, Erdinc Kamer, Ali D. Bozdag, Ercument Tarcan, Mehmet A. Onal, Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables. Canadian Journal of Surgery. ,vol. 52, pp. 31- 38 ,(2009)

Abbas Agaimy, Nikolaos Vassos, Werner Hohenberger, Roland S Croner, Arndt Hartmann, Peter H Wunsch, Impact of serosal involvement/extramural growth on the risk of synchronous and metachronous peritoneal spread in gastrointestinal stromal tumors: proposal for a macroscopic classification of GIST. International Journal of Clinical and Experimental Pathology. ,vol. 5, pp. 12- 22 ,(2012)

A. Le Cesne, I. Judson, D. Crowther, S. Rodenhuis, H.J. Keizer, Q. Van Hoesel, J.Y. Blay, J. Frisch, M. Van Glabbeke, C. Hermans, A. Van Oosterom, T. Tursz, J. Verweij, Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. ,vol. 18, pp. 2676- 2684 ,(2000) , 10.1200/JCO.2000.18.14.2676

P W Pisters, D H Leung, J Woodruff, W Shi, M F Brennan, Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. Journal of Clinical Oncology. ,vol. 14, pp. 1679- 1689 ,(1996) , 10.1200/JCO.1996.14.5.1679

Shreyaskumar R. Patel, Varsha Gandhi, Jan Jenkins, Nicholas Papadopolous, M. Andrew Burgess, Carl Plager, William Plunkett, Robert S. Benjamin, Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation Journal of Clinical Oncology. ,vol. 19, pp. 3483- 3489 ,(2001) , 10.1200/JCO.2001.19.15.3483

Antoine Italiano, Angela Cioffi, Paola Coco, Robert G. Maki, Patrick Schöffski, Piotr Rutkowski, Axel Le Cesne, Florence Duffaud, Antoine Adenis, Nicolas Isambert, Emmanuelle Bompas, Jean-Yves Blay, Paolo Casali, Mary Louise Keohan, Maud Toulmonde, Cristina R. Antonescu, Maria Debiec-Rychter, Jean-Michel Coindre, Binh Bui, Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib Annals of Surgical Oncology. ,vol. 19, pp. 1551- 1559 ,(2012) , 10.1245/S10434-011-2120-6

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt, One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor JAMA. ,vol. 307, pp. 1265- 1272 ,(2012) , 10.1001/JAMA.2012.347

Martin D McCarter, Cristina R Antonescu, Karla V Ballman, Robert G Maki, Peter WT Pisters, George D Demetri, Charles D Blanke, Margaret Von Mehren, Murray F Brennan, Linda McCall, David M Ota, Ronald P DeMatteo, American College of Surgeons Oncology Group, Intergroup Adjuvant Gist Study Team, None, Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence Journal of The American College of Surgeons. ,vol. 215, pp. 53- 59 ,(2012) , 10.1016/J.JAMCOLLSURG.2012.05.008

10.

J.-P. E. N. Pierie, The Effect of Surgery and Grade on Outcome of Gastrointestinal Stromal Tumors Archives of Surgery. ,vol. 136, pp. 383- 389 ,(2001) , 10.1001/ARCHSURG.136.4.383

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

来源期刊

我的账户

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

来源期刊

相似文章 6

Small-Bowel Tumors, Polyps, and Polyposis Syndromes

Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour

Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis

Gastrointestinal stromal tumors: A multidisciplinary challenge

Preoperative monocyte-to-lymphocyte ratio predicts recurrence in gastrointestinal stromal tumors.

Microscopic positive tumor margin does not increase the rate of recurrence in endoscopic resected gastric mesenchymal tumors compared to negative tumor margin.

我的账户